Node-negative T1-T2 anal cancer: radiotherapy alone or concomitant chemoradiotherapy?

Détails

ID Serval
serval:BIB_604964E43F26
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Node-negative T1-T2 anal cancer: radiotherapy alone or concomitant chemoradiotherapy?
Périodique
Radiotherapy and Oncology
Auteur(s)
Zilli T., Schick U., Ozsahin M., Gervaz P., Roth A.D., Allal A.S.
ISSN
1879-0887 (Electronic)
ISSN-L
0167-8140
Statut éditorial
Publié
Date de publication
2012
Volume
102
Numéro
1
Pages
62-67
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
PURPOSE: To evaluate the influence of concomitant chemotherapy on loco-regional control (LRC) and cancer-specific survival (CSS) in patients with T1-T2 N0 M0 anal cancer treated conservatively by primary radiotherapy (RT).
MATERIALS AND METHODS: Between 1976 and 2008, 146 patients with T1 (n=29) or T2 (n=117) N0 M0 anal cancer were treated curatively by RT alone (n=71) or by combined chemoradiotherapy (CRT) (n=75) consisting of mitomycin C±5-fluorouracil. Univariate and multivariate analyses were performed to assess patient-, tumor- and treatment-related factors influencing LRC and CSS.
RESULTS: With a median follow-up of 62.5 months (interquartilerange, 26-113 months), 122 (84%) patients were locally controlled. The five-year actuarial LRC, CSS and overall survival for the population were 81.4%±3.6%, 91.9%±2.6%, and 75.4%±3.9%, respectively. The five-year LRC and CSS for patients treated with RT alone and with CRT were 75.5%±6.0% vs. 86.8%±4.1% (p=0.155) and 88.5%±4.5% vs. 94.9%±2.9% (p=0.161), respectively. In the multivariate analysis, no clinical or therapeutic factors were found to significantly influence the LRC and CSS, while the addition of chemotherapy was of borderline significance (p=0.065 and p=0.107, respectively).
CONCLUSIONS: In the management of node negative T1-T2 anal cancer, LRC and CSS tend to be superior in patients treated by combined CRT, even though the difference was not significant. Randomized studies are warranted to assess definitively the role of combined treatment in early-stage anal carcinoma.
Mots-clé
Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Anus Neoplasms/pathology, Anus Neoplasms/therapy, Chemoradiotherapy/methods, Combined Modality Therapy, Female, Fluorouracil/administration & dosage, Humans, Male, Middle Aged, Mitomycin/administration & dosage, Neoplasm Staging, Survival Rate, Treatment Outcome
Pubmed
Web of science
Création de la notice
19/03/2012 20:02
Dernière modification de la notice
20/08/2019 15:17
Données d'usage